Tiziana Life Sciences #TILS – Acquires Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia April 27, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London – April 24, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory, autoimmune and infectious diseases, announced today that it pursuant to an asset purchase agreement it has acquired all of the intellectual property relating to a nanoparticle-based formulation of Actinomycin D (Act D; a.k.a. Dactinomycin), from Rasna Therapeutics, Inc. (“Rasna”) to expand its pipeline for a consideration of an initial…

Alan Green & Zak Mir discuss Open Orphan #ORPH, Tiziana Life #TILS & Bidstack #BIDS on ShareTalk TV April 24, 2020 – Posted in: Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Alan Green and Zak Mir, Share Talk‘s resident chartist, discuss today’s announcement from Open Orphan Plc #ORPH involving it’s London-based subsidiary HVIVO , plus Tiziana Life Sciences #TILS and it’s TZLS-501 anti IL6 treatment for #COVID1 patients with chronic respiratory conditions, plus Bidstack #BIDS unique platform to serve ads into the huge online gaming market. Link on the image to view. #podcast #disruptive #podcasting #sharetalk

Issue of Equity and Resulting Total Voting Rights. Update on AIM cancellation and migration to Nasdaq. – Posted in: Tiziana Life Sciences (TILS)

London, New York, 24 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued a total of 6,118,797 ordinary shares of 3 pence each (“Ordinary Shares”) credited as fully paid in respect of (i) the conversion of…

Alan Green talks Braveheart #BRH, Tiziana Life Sciences #TILS, Cadence Minerals #KDNC & ECR Minerals #ECR on Vox Markets podcast April 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

Alan Green discusses Braveheart Investments #BRH, Tiziana Life Sciences #TILS, Cadence Minerals #KDNC & ECR Minerals #ECR with Justin Waite on Vox Markets podcast. Interview is 39 minutes in.

Tiziana Life Sciences – Clinical pipeline update, resolutions seeking shareholder authority to issue new shares for cash & approval of proposed option grant – Posted in: Tiziana Life Sciences (TILS)

London, New York 21 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has convened a general meeting (the “GM”) to consider proposals to take increased authorities to allot shares; consider the replacement of share option awards and to adopt…

Alan Green talks markets, Eddie Stobart #ESL, Cadence Minerals #KDNC & Tiziana Life #TILS on the UK Investor Mag podcast April 16, 2020 – Posted in: Blog, Tiziana Life Sciences (TILS)

Alan Green discusses markets, Eddie Stobart #ESL, Cadence Minerals #KDNC & Tiziana Life #TILS with Jonathan Roy on the UK Investor Mag podcast.

Tiziana Life Sciences #TILS – Update Re: Block Listing Application April 15, 2020 – Posted in: Tiziana Life Sciences (TILS)

London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces further to the announcement made today regarding the Block Listing Application and “At The Market” Sales Agreement, an updated application has been made to AIM for a block admission…

Tiziana Life Sciences #TILS – Block Listing Application and “At The Market” Sales Agreement – Posted in: Tiziana Life Sciences (TILS)

London / New York 15 April 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that that it has entered into an “At the Market” or “ATM” Sales Agreement with Think Equity (a division of Fordham Financial Management, Inc.) to raise up to…

Mail on Sunday Market Watchlist – Tiziana Life Sciences #TILS April 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

There has been a scramble among AIM biotech companies to come up with a potential treatments for Coronavirus. One of the firms is Tiziana Life Sciences #TILS, listed on AIM and Nasdaq. The shares were in demand on Thursday when it said it had developed new technology to treat COVID-19 infections.

Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19 April 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London — April 9, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development…